Literature DB >> 9830022

Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.

X Wu1, R Kekuda, W Huang, Y J Fei, F H Leibach, J Chen, S J Conway, V Ganapathy.   

Abstract

We investigated the transport of cationic neurotoxins and neurotransmitters by the potential-sensitive organic transporter OCT3 and its steroid sensitivity using heterologous expression systems and also analyzed the expression of OCT3 in the brain. When expressed in mammalian cells, OCT3 mediates the uptake of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and the neurotransmitter dopamine. Competition experiments show that several cationic neuroactive agents including amphetamines interact with OCT3. When expressed in Xenopus laevis oocytes, OCT3-mediated MPP+ uptake is associated with inward currents under voltage-clamp conditions. The MPP+-induced currents are saturable with respect to MPP+ concentration, and half-maximal saturation (K0.5) occurs at about 25 microM MPP+ with membrane potential clamped at -50 mV. The K0.5 for MPP+ is markedly influenced by membrane potential. OCT3 is inhibited by several steroids, and beta-estradiol is the most potent inhibitor (Ki approximately 1 microM). The pattern of steroid sensitivity of OCT3 is different from that of OCT1 and OCT2 but correlates significantly with that of the extraneuronal monoamine transporter (uptake2). The transport characteristics and steroid sensitivity provide strong evidence for the molecular identity of OCT3 as uptake2. OCT3 is expressed in the brain as evidenced from Northern blot analysis, reverse transcription-polymerase chain reaction, and in situ hybridization using OCT3-specific probes. The molecular identity of the transcript hybridizing to the probe has been established by sequencing the reverse transcription-polymerase chain reaction product and also by the isolation of the OCT3 cDNA from a brain cDNA library. Regional distribution studies with in situ hybridization show that OCT3 is expressed widely in different brain regions, especially in the hippocampus, cerebellum, and cerebral cortex. OCT3 is likely to play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9830022     DOI: 10.1074/jbc.273.49.32776

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  94 in total

1.  Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters.

Authors:  I Wessler; E Roth; C Deutsch; P Brockerhoff; F Bittinger; C J Kirkpatrick; H Kilbinger
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats.

Authors:  Sarah White; Elizabeth Laurenzana; Howard Hendrickson; W Brooks Gentry; S Michael Owens
Journal:  Drug Metab Dispos       Date:  2011-06-01       Impact factor: 3.922

4.  Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.

Authors:  Shiro Itagaki; Vadivel Ganapathy; Horace T B Ho; Mingyan Zhou; Ellappan Babu; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2012-03-06       Impact factor: 3.922

5.  Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Drug Metab Dispos       Date:  2014-03-31       Impact factor: 3.922

6.  Organic cation transporter inhibition increases medial hypothalamic serotonin under basal conditions and during mild restraint.

Authors:  Na Feng; Christopher A Lowry; Jodi L Lukkes; Miles Orchinik; Gina L Forster; Kenneth J Renner
Journal:  Brain Res       Date:  2010-02-19       Impact factor: 3.252

7.  The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Authors:  Joao N Dos Santos Pereira; Sina Tadjerpisheh; Manar Abu Abed; Ali R Saadatmand; Babette Weksler; Ignacio A Romero; Pierre-Olivier Couraud; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

Review 8.  Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems.

Authors:  Akira Tsuji
Journal:  NeuroRx       Date:  2005-01

9.  Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Authors:  Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

10.  Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics.

Authors:  Britta Haenisch; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.